跳至主要内容
临床试验/NL-OMON39856
NL-OMON39856已完成不适用

Biomarkers predicting the effect of anti-TNF treatment in pediatric and adult inflammatory bowel disease. - Biomarkers of anti-TNF treatment in IBD

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
2 至 99(—)

入选标准

  • - anti-TNF naïve CD patients (6 years and older) who initiate anti-TNF treatment (infliximab (IFX) or adalimumab (ADA)) because of active luminal disease, failing treatment with immunomodulators and corticosteroids
  • - anti-TNF naïve UC patients (6 years and older) who initiate anti-TNF treatment (IFX or ADA) because of active disease despite corticosteroid treatment or because of failing of immunomodulators treatment
  • - anti-TNF naïve CD or UC patients (6 years and older) who initiate anti-TNF treatment (IFX or ADA) because of intolerance to treatment with immunomodulators or corticosteroids

排除标准

  • - IBD patients who initiate IFX or ADA immediately after diagnosis
  • - presence of severe perianal disease as primary indication to start anti-TNF treatment
  • - age younger then 6 years when anti-TNF maintenance treatment is initiated

研究者

相似试验